Serine/threonine-protein kinase OSR1

Description:

Description
  • Accession: O95747
  • Swissprot: OXSR1_HUMAN
  • Organism: Homo sapiens
  • Gene: OXSR1
  • Target class: Kinase

Drug Relations:

nintedanib
Bioactivity details MOA
ruxolitinib
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Although some small studies have suggested possibility of benefit from ruxolitinib in patients with COVID-19, it is not recommended the use of JAK inhibitors other than baricitinib for the treatment of COVID-19. Bioactivity details MOA
sunitinib
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA. Bioactivity details MOA